Background: Previous studies of cancer patients investigated the effect of psychological treatment on basal endocrine and immune values. Using a randomized experiment, we explored the effect of a 13-week experiential-existential group psychotherapy (EEGP) program on the reactivity to a speech task in breast cancer patients. We explored whether changes in cardiovascular and immune reactivity to a speech task over the 3-month period correlated with changes in psychological distress and emotional expression. Methods: Patients who had been treated for early-stage breast cancer and who were diagnosed as having either positive axillary lymph nodes or distant metastases were randomly assigned to either EEGP or a waiting list control (WLC) condition. We continuously recorded heart rate (HR), diastolic (DBP) and systolic blood pressure (SBP) in response to the speech task before and after treatment. We also measured lymphocyte proliferation to pokeweed (PWM) and phytohemagglutinin (PHA), and natural killer cell activity (NKCA) as well as peripheral blood lymphocyte distributions in blood samples that were drawn before, during and after the speech task. Results: Patients in EEGP had smaller increases in natural killer (NK) cells induced by the speech task after treatment versus task-induced values observed at study entry and greater than pre-/posttreatment changes seen in patients randomized to the WLC. A similar pattern emerged with respect to NKCA over the intervention period, which was independent of the changes in NK cells. There were no differences between patients assigned to EEGP and WLC in HR, DBP and SBP responses as well as in changes in PWM- and PHA-induced lymphocyte proliferation in response to the speech task measured before and after the 3-month intervention period. Individual differences in pre-/posttreatment increases in emotional expression but not in psychological distress were significantly associated with smaller changes in the number and function of NK cells over the 3-month period. Conclusions: These findings may indicate that emotional expression during EEGP may render breast cancer patients more comfortable expressing their emotional responses to the speech challenge, which, in turn, results in smaller stress-induced changes in NK cells and function.

Keywords:
Breast cancer, Tamoxifen, Nonsteroidal antiestrogenic treatment, Psychotherapy, experiential-existential, Randomized trial, Immune system, Natural killer cells, Endocrine system, Cardiovascular reaction, Acute psychological stress
1.
Spiegel D, Bloom J, Kraemer H, Gottheil E: Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 1989;ii:888–891.
2.
Watson M, Ramirez A: Life events, personality, behavior and cancer; in Watson M, Cooper C (eds): Cancer and Stress: Recent Research. Chichester, Wiley & Sons, 1991.
3.
Mulder C, van der Pompe G, Spiegel D, Antoni MH, de Vries M: Do psychosocial factors influence the course of breast cancer? Psychooncology 1992;1:155–167.
4.
Calabrese JR, Kling MA, Gold PW: Alterations in immunocompetence during stress, bereavement, and depression: Focus on neuroendocrine regulation. Am J Psychiatry 1987;144:1123–1134.
5.
Herbert TB, Cohen S: Stress and immunity in humans: A meta-analytic review. Psychosom Med 1993;55:364–379.
6.
Herbert TB, Cohen S: Depression and immunity: A meta-analytic review. Psychol Bull 1993;113:472–486.
7.
van der Pompe G, Antoni MH, Mulder CL, Heijnen CJ, Goodkin K, de Graeff A, Garssen B, de Vries MJ: Psychoneuroimmunology and the course of breast cancer: An overview. Psychooncology 1994;3:271–288.
8.
Schedlowski M, Jung C, Schimanski G, Tewes U, Schmoll HJ: Effects of behavioral intervention on plasma cortisol and lymphocytes in breast cancer patients: An exploratory study. Psychooncology 1995;3:181–187.
9.
Spiegel D, Spira J: Supportive-Expressive Group Therapy: A Treatment Manual of Psychosocial Intervention for Women with Recurrent Breast Cancer. Stanford, Stanford University School of Medicine, Psychosocial Treatment Laboratory, 1991.
10.
Benschop RJ, Geenen R, Mills PJ, Mills PJ, Naliboff BD, Kiecolt-Glaser JK, Herbert TB, van der Pompe G, Miller GE, Matthews KA, Godaert GLR, Gilmore SL, Glaser R, Heijnen CJ, Dopp JM, Bijlsma JWJ, Solomon GF, Cacioppo JT: Cardiovascular and immune responses to acute psychological stress in young and old women: A meta-investigation. Psychosom Med 1998;60:290–296.
11.
van der Pompe G, Antoni MH, Visser A, Heijnen CJ: Effect of mild acute stress on immune cell distribution and natural killer cell activity in breast cancer patients. Biol Psychol 1998;48:21–35.
12.
van der Pompe G, Antoni MH, Heijnen CJ: The effects of surgical stress and psychological stress on the immune function of operative cancer patients. Psychol Health 1998;13:1015–1026.
13.
Berry J, Green B, Matheson D: Modulation of natural killer cell activity by tamoxifen in stage 1 postmenopausal breast cancer patients. Eur J Cancer Clin Oncol 1987;23:517–520.
14.
Tichatschek E, Zielinksi C, Muller CH, Sevelda P, Kubista E, Czerwenka K, Spona J, Wolf H, Eibl M: Long-term influence of adjuvant therapy on natural killer cell activity in breast cancer. Cancer Immunol Immunother 1988;27:278–282.
15.
Brenner B, Margolese R: The relationship of chemotherapeutic and endocrine intervention on natural killer cell activity in human breast cancer. Cancer 68:482–488.
16.
Saab PG, Liabre MM, Hurwitz BE, Frame CA, Reineke LJ, Fins AI, McCalla J, Cieply LK, Schneiderman N: Myocardial and peripheral vascular responses to behavioral challenges and their stability in black and white Americans. Psychophysiology 1992;29:384–397.
17.
Yalom I: Existential Psychotherapy. New York, Basic Books, 1983.
18.
Spencer SM, Lehman JM, Wynings C, Arena, Carver CS, Antoni MH, Derhagopian RP, Ironson G, Love N: Concerns of a multi-ethnic sample of early stage breast cancer patients and relations to psychosocial well being. Health Psychol 1999;18:159–168.
19.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–571.
20.
Bouman TK, Luteijn F, Albersnagel FA, van der Ploeg FAE: Enige ervaringen met de Beck Depression Inventory (BDI). Gedrag 1985;13:13–24.
21.
Spielberger CD: Test Manual for the State-Trait Anxiety Inventory-STAI Form Y. Palo Alto, Consulting Psychologist Press, 1980.
22.
van der Ploeg HM, Defares PD, Spielberger CD: Handleiding bij Zelf-beoordelings-vragenlijsten (ZBV). Lisse, Swet & Zeitlinger, 1980.
23.
McNair DM, Lorr M, Droppleman LF: Profile of Mood States. San Diego, Educational and Industrial Testing Service, 1971.
24.
Wald FDM, Mellenberg GJ: De verkorte versie van de Nederlandse vertaling van de Profile of Mood States (POMS). Ned Tijdschr Psychol 1990;45:86–99.
25.
van der Ploeg HM, Kleijn W, Mook J, van Donge M, Pieters A, Leer JW: Rationality and antiemotionality as a risk factor for cancer: Concept differentiation. J Psychosom Res 1989;33:217–225.
26.
van der Pompe G, Duivenvoorden HJ, Antoni MH, Visser A, Heijnen CJ: Effectiveness of a short-term group psychotherapy program on endocrine and immune function in breast cancer patients: An empirical exploration. J Psychosom Res 1997;42:453–466.
27.
Benschop RJ, Nieuwenhuis EES, Tromp EAM, Godaert GLR, Ballieux RE, van Doornen LJP: Effects of β-adrenergic blockade on immunological and cardiovascular changes induced by stress. Circulation 1994;89:762–769.
28.
Bachen EA, Manuck SB, Cohen S, Raible R, Herbert TB, Rabin BS: Adrenergic blockade ameliorates cellular immune responses to mental stress in humans. Psychosom Med 1995;57:366–372.
29.
Fava GA, Sonino N: Psychosomatic medicine: Emerging trends and perspectives. Psychother Psychosom 2000;69:184–197.
30.
Marks I: Is a paradigm shift occurring in brief psychological treatment? Psychother Psychosom 1999;68:169–170.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.